About Scleroderma >
COVID-19 >
+ info


Safety and Immunogenicity of SARS CoV2 Vaccine Study

Researchers at the University of Manitoba are conducting a research study to investigate how people with autoimmune conditions and those who have reduced immune systems due to medication react to the vaccines being used to prevent COVID-19 illness in Canada.

If you are interested in furthering the understanding of the effect of the vaccines in scleroderma patients by participating in this study, please contact cov2vaccinestudy@hsc.mb.ca or call 204 787-4734 or 204-787-4275 for more information.

COVID-19 presents important challenges for people affected by Scleroderma. This page provides available resources and pertinent information for Scleroderma patients, as well as initiatives to support the organization and patients during these difficult times.

If you have questions about mental health, well-being, or coping with COVID-19, SPIN Director, Dr. Brett Thombs, and the SPIN Team are ready to provide answers. Please submit your questions here.

Vaccine news

With the approval of several vaccines in Canada for Covid-19, there are many questions about the safety and efficacy of the vaccines for people living with scleroderma.

The Scleroderma Foundation in the United States has provided information and recommendations on COVID-19 vaccines which can be accessed using the link below. It has highly credible information from some of the top experts in the world. Scleroderma Manitoba recommends that you discuss medical decisions regarding the vaccine with your doctor.

Scleroderma Foundation: Questions and Answers Regarding the COVID-19 Vaccine


SPIN Series: Living with Covid (Concluded)

SPIN (The Scleroderma Patient Information Network) offered weekly educational webinars in February and March. Watch recordings of the sessions using the links below:

02/02: Healthy Information Management with Laura Dyas

02/10: Worry management with Ghassan El-Baalbaki

02/17: Relaxation techniques with Ghassan El-Baalbaki

02/24: Adapted home exercise with Kelsey Ellis & Delaney Duchek

03/03: Home activity engagement with Laura Bustamante


More answers to your questions

Immunosuppression is a risk factor, and having an interstitial lung disease (ILD) or Scleroderma without an ILD puts you at a slightly higher risk.

If you have questions, watch this video forum captured on March 21, 2020.

Scleroderma & COVID-19: A conversation with the experts 

Participants were invited to submit their questions concerning COVID-19 and Scleroderma in advance via an online Qualtrics questionnaire or to ask their questions directly to a team of five experienced panelists, Mrs. Maureen Sauvé, Dr. Janet Pope, Dr. John Varga, Dr. Don Sheppard and Dr. Brett Thombs, by typing them into the discussion section of GotoMeeting.

Access a transcript of the questions and answers here.

More information

COVID-19 and Scleroderma Q&A web-icon-pdf

Scleroderma Manitoba endorses The Scleroderma Foundation on COVID-19 for people with scleroderma: 
Information and Recommendations from The Scleroderma Foundation

Make the difference!

Every donation and effort help us to make a difference to advance research and to support people affected by scleroderma in Manitoba.  

Support research and scleroderma patients here.